Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony L Cunningham

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
Journal of Virological Methods|June 16, 2009
Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplificationBin Wang, Dominic E Dwyer, Choo Beng Chew, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 26, 2023
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitorAmit Bar-Or, Anne H Cross, Anthony L Cunningham, et al.
Virology|May 27, 2005
Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndromeLachlan Gray, Jasminka Sterjovski, Melissa Churchill, et al.
Vaccine|September 21, 2019
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trialsDavid O Willer, Lidia Oostvogels, Anthony L Cunningham, et al.
Antimicrobial Agents and Chemotherapy|December 9, 2015
Abalone Hemocyanin Blocks the Entry of Herpes Simplex Virus 1 into Cells: a Potential New Antiviral StrategyNegar Talaei Zanjani, Monica Miranda-Saksena, Peter Valtchev, et al.
Human Vaccines & Immunotherapeutics|April 30, 2020
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trialsRomulo Colindres, Valentine Wascotte, Alain Brecx, et al.
Retrovirology|November 27, 2007
Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stagesJing Qin Wu, Bin Wang, Larissa Belov, et al.
RMD Open|August 13, 2025
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudyKevin L Winthrop, Justin Klaff, Sara K Penn, et al.
The Journal of Infectious Diseases|April 25, 2008
Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirusBrett A Lidbury, Nestor E Rulli, Andreas Suhrbier, et al.
Journal of Virology|December 15, 2015
The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from NeuronsRussell J Diefenbach, April Davis, Monica Miranda-Saksena, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
Journal of Virological Methods|June 16, 2009
Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplificationBin Wang, Dominic E Dwyer, Choo Beng Chew, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 26, 2023
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitorAmit Bar-Or, Anne H Cross, Anthony L Cunningham, et al.
Virology|May 27, 2005
Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndromeLachlan Gray, Jasminka Sterjovski, Melissa Churchill, et al.
Vaccine|September 21, 2019
Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trialsDavid O Willer, Lidia Oostvogels, Anthony L Cunningham, et al.
Antimicrobial Agents and Chemotherapy|December 9, 2015
Abalone Hemocyanin Blocks the Entry of Herpes Simplex Virus 1 into Cells: a Potential New Antiviral StrategyNegar Talaei Zanjani, Monica Miranda-Saksena, Peter Valtchev, et al.
Human Vaccines & Immunotherapeutics|April 30, 2020
Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trialsRomulo Colindres, Valentine Wascotte, Alain Brecx, et al.
Retrovirology|November 27, 2007
Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stagesJing Qin Wu, Bin Wang, Larissa Belov, et al.
RMD Open|August 13, 2025
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudyKevin L Winthrop, Justin Klaff, Sara K Penn, et al.
The Journal of Infectious Diseases|April 25, 2008
Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirusBrett A Lidbury, Nestor E Rulli, Andreas Suhrbier, et al.
Journal of Virology|December 15, 2015
The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from NeuronsRussell J Diefenbach, April Davis, Monica Miranda-Saksena, et al.
Pageof 21